Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 15, 2015

View Archived Issues

Genomic analysis of PDXs to identify resistance/response mechanisms to anti-EGFR in CRC

Genetic profiling of early lung neoplasms, primary lung tumors and circulating DNA

Precision medicine to identify genes influencing response to hydrochlorothiazide

Results from UK Biobank initiative identify new genes for respiratory disorders

Novel mutations causing Hunter syndrome identified in case series report

Actelion Pharmaceuticals divulges CXCR3 modulators

Merck & Co. reports HIV reverse transcriptase inhibitors

NIH awards several grants to Aridis

Izun Pharmaceuticals reports data from phase II trial in diabetic foot ulcers

Preclinical data on VS-105's effect on BMD

NPSP-795 shows promise for ADH1

Institute of Human Virology begins phase I trial of HIV vaccine candidate

Theravance submits IND for neprilysin inhibitor TD-0714

3SBio enters licensing deal with Alteogen for ALT-P7 in China

GNI subsidiary files NDA in China for Amnolake

Synjardy now available in U.S. pharmacies

Baricitinib demonstrates superiority to adalimumab in phase III study

FDA awards QIDP designation to Mino-Lok

Astex Therapeutics reports FGFR inhibitors

Merck & Co. patents TrkA inhibitors

Chinese Ebola vaccine enters first overseas trial

Roche discloses autotaxin inhibitors

Pfizer and UICC award 20 grants to support projects in metastatic breast cancer

Protalix sells share in Elelyso collaboration agreement to Pfizer

Merck KGaA relaunches brand identity

Bristol-Myers Squibb and Five Prime sign CSF-1R antibody license and collaboration agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...